ELAN REPORTS 47% REDUCTION IN GASTROINTESTINAL SIDE EFFECTS WITH NAPRELAN NAPROXEN V. SYNTEX' NAPROSYN IN COMPARISON TRIALS; VERELAN SALES ARE $100 MIL.

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".